Tom Blackburn | |
|---|---|
| Born | 1949 (age 74–75) |
| Nationality | United Kingdom |
| Alma mater | |
| Occupation | Industrial pharmacologist |
| Employers |
|
Tom Blackburn FBPharmacolS, FRSB (born 1949) is a British industrial pharmacologist.
Blackburn studied at both the University of Nottingham and Manchester University, and worked as a senior manager at ICI Pharmaceuticals, Beecham Pharmaceuticals SmithKline Beecham, Synaptic Pharmaceutical Corporation and Helicon Therapeutics.[1]
He is the author of over 100 scientific papers, reviews and book chapters and holds over 20 patents.[1] He is President Emeritus of the British Pharmacological Society and is a member of the American College of Neuropsychopharmacology.[1]
He was elected an Honorary Fellow of the British Pharmacological Society (Hon FBPharmacolS) in 2014 and is a Fellow of the Royal Society of Biology (FRSB).[2]
References
- 1 2 3 Caroline Overy; Tilli Tansey, eds. (2013). Drugs Affecting 5-HT Systems. Wellcome Witnesses to Contemporary Medicine. History of Modern Biomedicine Research Group. ISBN 978-0-902238-87-9. Wikidata Q29581800.
- ↑ "Dr Thomas Blackburn". British Pharmacological Society. Retrieved 3 August 2017.
External links
- Tom Blackburn on the History of Modern Biomedicine Research Group website
- Interview with Blackburn playlist on YouTube - conducted by Professor Tilli Tansey, for the History of Modern Biomedicine Research Group, 22 February 2016 (seven parts)
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.